![David Levinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Levinson
Operationeel Directeur bij Pearl Energy Investment Management, LLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
William J. Quinn | M | 53 |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas.
BQ Capital Partners
![]() BQ Capital Partners Financial ConglomeratesFinance BQ Capital Partners provides investment services. The private company is based in Irving, TX. | 11 jaar |
A. Chris Aulds | M | 61 |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | - |
Kevin MANUEL Pohler | M | 32 |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | - |
Chris Sorrells | M | 55 |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | 3 jaar |
Stewart A. Coleman | M | - |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | 9 jaar |
Deena Roubal | F | - |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | 9 jaar |
Alex Dieste | M | - |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | - |
Steven Cobb | M | - |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | 9 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Domingo Rodriguez | M | 62 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 jaar |
Timothy Sear | M | 86 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 jaar |
James Dalton | M | 61 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 jaar |
Robert Karr | M | 75 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 6 jaar |
Jeffrey G. Hesselberg | M | 65 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Jason Shackelford | M | 48 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Kenneth Robinson | M | 69 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
J. Glass | M | 77 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
John Pontius | M | 68 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 13 jaar |
Michael Carter | M | 86 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Barrington John Albert Furr | M | 80 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 jaar |
Andrew Clarkson | M | 86 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Griffin Cooper | M | - |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | - |
Chris Warley | M | - |
Pearl Energy Investment Management, LLC
![]() Pearl Energy Investment Management, LLC Investment ManagersFinance Pearl Energy Investment Management, LLC (Pearl Energy Investment) is a private equity firm founded in 2015 by William J. Quinn and Chris Aulds. The firm is headquartered in Dallas, Texas. | 2 jaar |
Mary Ann Johnston | M | 52 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Michael Brown | M | - |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Ronald A. Morton | M | 65 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
McDavid Stilwell | M | 53 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 7 jaar |
Rosemary Mazanet | M | 68 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 8 jaar |
Shontelle Dodson | M | 53 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Christopher K. West | M | 57 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
Gregory Deener | M | 62 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 7 jaar |
K. Barnette | M | 56 |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 12 jaar |
David Dickason | M | - |
GTx, Inc.
![]() GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 32 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- David Levinson
- Persoonlijk netwerk